NO20062594L - Transdermal delivery system of hormones without penetration enhancers - Google Patents

Transdermal delivery system of hormones without penetration enhancers

Info

Publication number
NO20062594L
NO20062594L NO20062594A NO20062594A NO20062594L NO 20062594 L NO20062594 L NO 20062594L NO 20062594 A NO20062594 A NO 20062594A NO 20062594 A NO20062594 A NO 20062594A NO 20062594 L NO20062594 L NO 20062594L
Authority
NO
Norway
Prior art keywords
hormones
patch
penetration enhancers
delivery system
transdermal delivery
Prior art date
Application number
NO20062594A
Other languages
Norwegian (no)
Other versions
NO341989B1 (en
Inventor
Michael Dittgen
Thomas Langguth
Dirk Schenk
Stefan Bracht
Petra Huber
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34702342&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20062594(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20062594L publication Critical patent/NO20062594L/en
Publication of NO341989B1 publication Critical patent/NO341989B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7076—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Abstract

Den foreliggende oppfinnelsen angår et plaster som omfatter et legemiddelinneholdende lag med lavt innhold av hormon, slik som gestoden, og eventuelt et østrogen (f.eks. etiny-lestradiol). Ved administrasjon av plasteret til en kvinne, oppnås plasmanivåer på minst 1,0 ng/ml av gestoden ved steady-state-betingelser uten behov for inkorporering av penetrasjonsenhancere eller permeasjonsenhancere i det legemiddelinneholdende laget. Tilfredsstillende plasmanivaer i hormonene oppnås også gjennom en periode på minst 1 uke, idet plasteret gjøres anvendelig til bruk ved svangerskapsforebygging hos kvinner med et prinsipp om administrasjon av plastrene én gang ukentlig.The present invention relates to a patch comprising a low-hormone drug-containing layer, such as the gestod, and optionally an estrogen (e.g., ethinylestradiol). When administering the patch to a woman, plasma levels of at least 1.0 ng / ml of the gestode are achieved under steady-state conditions without the need for incorporation of penetration enhancers or permeation enhancers into the drug-containing layer. Satisfactory plasma levels of the hormones are also achieved over a period of at least 1 week, the patch being made usable for use in contraception in women with a principle of administering the patches once weekly.

NO20062594A 2003-12-12 2006-06-06 Transdermal administration of hormones without the need for penetration enhancers. NO341989B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52871803P 2003-12-12 2003-12-12
EP03078881 2003-12-12
PCT/IB2004/052752 WO2005058287A2 (en) 2003-12-12 2004-12-10 Transdermal delivery system of hormones without penetration enhancers

Publications (2)

Publication Number Publication Date
NO20062594L true NO20062594L (en) 2006-07-10
NO341989B1 NO341989B1 (en) 2018-03-12

Family

ID=34702342

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062594A NO341989B1 (en) 2003-12-12 2006-06-06 Transdermal administration of hormones without the need for penetration enhancers.

Country Status (15)

Country Link
JP (1) JP4965263B2 (en)
KR (1) KR101168449B1 (en)
CN (1) CN1913878B (en)
AU (1) AU2004298930B2 (en)
BR (1) BRPI0417530B8 (en)
CA (1) CA2549916C (en)
CU (1) CU23868B1 (en)
EA (1) EA011160B1 (en)
EC (1) ECSP066694A (en)
IL (1) IL176112A (en)
MX (1) MXPA06006682A (en)
NO (1) NO341989B1 (en)
NZ (1) NZ548091A (en)
WO (1) WO2005058287A2 (en)
ZA (1) ZA200605713B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME00147B (en) 2003-02-21 2010-10-10 Schering Ag Uv stable transdermal therapeutic plaster
US8962013B2 (en) 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
DE102005050729A1 (en) * 2005-10-19 2007-04-26 Schering Ag Method of preventive on-demand hormonal contraception
FR2900048B1 (en) * 2006-04-21 2012-11-16 Oreal COMPOSITIONS COMPRISING A DIPHENYL-METHANE HYDROXYLATED DERIVATIVE
ES2617334T3 (en) 2010-09-06 2017-06-16 Bayer Intellectual Property Gmbh Low-dose transdermal patches with high drug release
DE102010040299A1 (en) * 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)
AU2015203180B2 (en) * 2010-09-06 2016-06-30 Bayer Intellectual Property Gmbh Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)
AU2013212005A1 (en) * 2012-01-27 2014-07-31 Agile Therapeutics, Inc. Transdermal hormone delivery
US20180125860A1 (en) * 2015-05-18 2018-05-10 Agile Therapeutics, Inc. Contraceptive Compositions and Methods for Improved Efficacy and Modulation of Side Effects

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE58909570D1 (en) * 1988-10-27 1996-02-22 Schering Ag DEPOSIT CONTAINING MEANS OF TRANSDERMAL APPLICATION
US5512292A (en) * 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
EP0555360A1 (en) * 1990-10-29 1993-08-18 Alza Corporation Transdermal contraceptive formulations, methods and devices
DE4329242A1 (en) * 1993-08-26 1995-03-02 Schering Ag Agent for transdermal application containing gestodenester
DE4405898A1 (en) * 1994-02-18 1995-08-24 Schering Ag Transdermal therapeutic systems containing sex steroids
WO1996015776A1 (en) * 1994-11-18 1996-05-30 Hisamitsu Pharmaceutical Co., Inc. Percutaneously absorbable patch
JP3534775B2 (en) * 1995-06-07 2004-06-07 オーソ―マクニール ファーマシューティカル，インコーポレイテッド Transdermal patches and methods for administering 17-deacetylnorgestimate alone or in combination with estrogens
JP4346696B2 (en) * 1996-05-28 2009-10-21 久光製薬株式会社 Transdermal therapeutic device
JP4167750B2 (en) * 1997-04-16 2008-10-22 久光製薬株式会社 Transdermal absorption base and percutaneous absorption preparation containing the base
JP4399044B2 (en) * 1998-10-14 2010-01-13 久光製薬株式会社 Absorption enhancer and transdermal absorption preparation comprising the absorption enhancer
DE19906152B4 (en) * 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Active substance-containing laminates for transdermal systems
WO2001001990A1 (en) * 1999-07-01 2001-01-11 Hisamitsu Pharmaceutical Co., Inc. Adhesive preparation for percutaneous absorption
DE10053375C1 (en) * 2000-10-27 2002-01-24 Lohmann Therapie Syst Lts Transdermal therapeutic system with light-sensitive agent in polymer matrix and backing, useful for therapy with e.g. nicotine, nifedipine, lacidipine, gestagen, vitamin B 12 or antibiotic, contains colorless ultraviolet absorber
US20020106402A1 (en) * 2000-12-05 2002-08-08 Hartwig Rod Lawson Crystallization inhibition of drugs in transdermal drug delivery systems and methods of use

Also Published As

Publication number Publication date
BRPI0417530B8 (en) 2021-05-25
CU20100143A7 (en) 2011-10-31
BRPI0417530A (en) 2007-03-13
IL176112A0 (en) 2006-10-05
KR101168449B1 (en) 2012-07-25
CN1913878B (en) 2010-05-26
IL176112A (en) 2011-02-28
NZ548091A (en) 2009-12-24
WO2005058287A2 (en) 2005-06-30
CU23868B1 (en) 2013-03-27
CN1913878A (en) 2007-02-14
KR20060128910A (en) 2006-12-14
ECSP066694A (en) 2006-10-31
EA011160B1 (en) 2009-02-27
AU2004298930B2 (en) 2009-11-26
CA2549916A1 (en) 2005-06-30
EA200601089A1 (en) 2006-12-29
JP4965263B2 (en) 2012-07-04
AU2004298930A1 (en) 2005-06-30
MXPA06006682A (en) 2006-08-11
BRPI0417530B1 (en) 2018-01-23
JP2007513938A (en) 2007-05-31
WO2005058287A3 (en) 2006-03-02
NO341989B1 (en) 2018-03-12
CA2549916C (en) 2013-09-17
ZA200605713B (en) 2008-01-08

Similar Documents

Publication Publication Date Title
NO20062594L (en) Transdermal delivery system of hormones without penetration enhancers
CY1115064T1 (en) HYDRAULIC INTERDERATIVE HYMN TRADE SYSTEM WITHOUT LEADING AID
DK1089722T3 (en) Transdermal matrix type patch for steroid hormones
NO20063171L (en) Endoparasitic compositions for topical application
HUP9904369A2 (en) Transdermal drug delivery matrix for coadministering estradiol and another steroid
FI7341U1 (en) Transdermal patch for fentanyl delivery
HUP9902952A1 (en) Water-soluble pharmaceutical copositions in an ionic complex and the use thereof
NO20030961L (en) Pharmaceutical preparations and method of treatment of hypogonadism
NO20062679L (en) New 17β-hydroxysteroid dehydrogenase type 1 inhibitors
CY1105716T1 (en) Transdermal patch UV stable
DK1283700T3 (en) Pharmaceutical sustained release preparations for parenteral administration of biologically active hydrophilic compounds
DK0949925T3 (en) Flat drug form for placement in the oral cavity with release there of buprenorphine or a pharmacologically comparable substance, and method of preparation thereof
MXPA02009275A (en) Method for preparing high pressure high shear dispersions containing physiologically active ingredients.
DE69735656D1 (en) New formulations for the transdermal administration of fluoxetine
AU2003253506A1 (en) Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
WO2001039752A3 (en) Transdermal therapeutic system containing highly volatile active ingredients
ATE464878T1 (en) PHARMACEUTICAL COMPOSITION FOR NASAL USE OF FENTANYL
CA2403949A1 (en) Transdermal therapeutic system for the delivery of lerisetron
NO990498L (en) 19-nor-cholansteroids as neurochemical initiators of change in human hypothalamic function
PE20050665A1 (en) SELECTIVE ESTROGENS OF 8ß-VINYL-ESTRA-1,3,5 (10) -TRIEN-3,17ß-DIOL AND 17ß-FLUOR-9-VINYL-ESTRA-1,3,6 (10) -TRIEN-3,16ALPHA -DIOL
WO2005046600A3 (en) Transdermal tulobuterol delivery
DE50208253D1 (en) TRANSDERMAL THERAPEUTIC SYSTEM FOR THE ADMINISTRATION OF THE PARTIAL DOPAMINE D2 AGONIST ARIPIPRAZOLE
KR960021015A (en) Transdermal Patches
CU20060121A7 (en) TRANSDERMAL ADMINISTRATION HORMONES THAT DO NOT NEED PENETRATION POTENTIATORS
DE69918124D1 (en) FORMULATIONS FOR TRANSDERMAL ADMINISTRATION OF FENOLDOPAM

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE

MM1K Lapsed by not paying the annual fees